Abiopharma

🔍 Brunn Carsten (Director)

Company: Cartesian Therapeutics, Inc. (RNAC)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 143,200 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 347,296.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 415,700 shares of Employee Stock Option (right to buy) at $6.76 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-01 | equity_swap_involved: 0 | shares_owned_after: 415,700.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030.
• F2: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.